ÂÜÀòÂÒÂ×

Katherine Bell-McGuinn currently serves as Chief Medical Officer at 858 Therapeutics, a position held since November 2023. Prior to this role, Katherine held various leadership positions at AbbVie from March 2020 to October 2023, including Vice President for both Oncology Early Development and Clinical Oncology, as well as Group Medical Director. Katherine's experience also includes roles at Eli Lilly and Company as a Medical Fellow and Senior Medical Advisor in Oncology from August 2016 to March 2020, and at Memorial Sloan Kettering Cancer Center as Assistant Attending Physician from July 2007 to June 2016. Katherine's educational background includes a Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center, an Internal Medicine Residency at The Johns Hopkins Hospital, an M.D./Ph.D. in Pharmacology from The Johns Hopkins University School of Medicine, and Bachelor of Science and Bachelor of Arts degrees in Chemistry and Mathematics, respectively, from Texas Lutheran University.